Patient-rated outcomes (PRO) in a randomized trial of first-line chemotherapy with capecitabine (C), bevacizumab (B), and mitomycin-C (M) for metastatic colorectal cancer: The AGITG MAX trial.

摘要: e14036 Background: We previously reported that adding B (± M) to C improved progression-free survival (PFS) in patients having first-line chemotherapy for metastatic colorectal cancer (Abs 4023, ASCO 2009). Here we compare the effects of these treatments on patients' ratings symptoms, functions, overall quality life, and acceptability chemotherapy. Methods: Subjects were randomly allocated C, CB or CBM. The following PRO questionnaires (number items) completed at weeks 0, 3, 6, 9, 12 then 6-weekly until progression: Euroqol-5D (5), Utility Based Quality Life Questionnaire - Cancer (30), Chemotherapy Acceptability (15). Generalized estimating equation regression models used calculate differences between treatment groups (D), 95% confidence intervals (CI), p-values accounted baseline values, repeated measurements different durations. Analyses 2-tailed, not adjusted multiple comparisons, expressed a scale from 0 (...